Neurologists See CAR T Potential in Neuro-Immune Diseases, but Safety and Logistics Will Shape Adoption
核心洞察
A July 2026 survey of 92 neurologists found 77% believe CAR T therapies could make current standards of care obsolete in neuro-immune diseases if proven safe and effective.
Safety is the clearest adoption barrier, with 74% of neurologists citing the safety profile as a major concern, including cytokine release syndrome and neurotoxicity.
Cartesian Therapeutics' Descartes-08 (BCMA (搜索)-directed) and Kyverna's miv-cel (搜索) (anti-CD19 (搜索)) lead physician familiarity among investigational CAR T programs.
Cell therapy is emerging as a potentially important new treatment approach across neuro-immune diseases, with chimeric antigen receptor T (CAR T) cell therapy programs advancing in generalized myasthenia gravis (搜索) (gMG), multiple sclerosis (搜索) (MS), chronic inflammatory demyelinating polyneuropathy (搜索) (CIDP), neuromyelitis optica spectrum disorder (搜索) (NMOSD), stiff person syndrome (搜索) (SPS), myelin oligodendrocyte inflammatory disorder (搜索) (MOGAD), and multifocal motor neuropathy (搜索) (MMN). New research from Spherix Global Insights (搜索) finds that 77% of surveyed neurologists believe that, if proven safe and effective, CAR T therapies could make current standards of care obsolete and redefine the management of neuro-immune diseases.
Findings from Spherix Global Insights (搜索)' Special Topix™: Cell Therapy in Neuro-Immune Indications (US) 2026, based on a July 2026 survey of 92 neurologists, show that neurologists broadly recognize the potential for CAR T therapies to offer deeper, more durable, and potentially curative, responses in highly refractory patients. However, their enthusiasm remains tempered by limited long-term evidence and unanswered questions around safety, patient selection, and real-world implementation.
Safety Emerges as the Primary Adoption Barrier
Safety is the clearest factor shaping physician expectations, with 74% agreeing that the safety profile of CAR T therapies will be a major barrier to adoption. Concerns center on cytokine release syndrome, neurotoxicity, lymphodepleting preconditioning regimens, and the need for long-term safety follow-up. Durable remission data and comparative evidence against established therapies will be critical in defining the role of emerging CAR T options, particularly whether they remain highly specialized later-line therapies for a limited subset of refractory patients or, with compelling evidence, move toward broader use over time.
Logistics and Care Delivery Will Influence Uptake
Operational considerations may prove equally important. Spherix research indicates that neurologists expect these treatments to be delivered initially through specialized treatment centers at academic medical centers and through shared-care models in collaboration with hematologist-oncologists, rather than entirely within neurology. Access to experienced centers, well-defined referral pathways, and logistical support are therefore likely to influence adoption alongside clinical outcomes.
Pipeline Leaders: Descartes-08 and Miv-cel
The pipeline includes multiple cell therapy programs advancing across neuro-immune indications, most commonly gMG and MS. While neurologist familiarity and interest vary across investigational programs, Cartesian Therapeutics' Descartes-08, an investigational BCMA (搜索)-directed CAR T therapy, has emerged as particularly top of mind, with the highest physician familiarity among the pipeline therapies evaluated. After reviewing available clinical data, nearly half of neurologists reported a highly favorable impression of Descartes-08 as a potential treatment for gMG. Kyverna Therapeutics' miv-cel (搜索) (KYV-101), an investigational anti-CD19 (搜索) CAR T therapy, ranked second in physician familiarity, with 37% of neurologists also reporting that they are extremely interested in having the therapy approved and available. Together, the findings highlight physician interest across multiple cell therapy targets as the neuro-immune pipeline advances.
"Neurologists clearly see a potential role for CAR T in neuro-immune disease, but the path to adoption will depend on much more than efficacy alone," said Georgiana Kuhlmann, CNS Senior Insights Director, Spherix Global Insights (搜索). "The therapies that ultimately gain traction will need to demonstrate durable benefit while also addressing the practical realities of safety monitoring, referral, treatment-center access, and patient selection," Kuhlmann added.
The Path to Broader Adoption
As clinical evidence for cell therapy in neuro-immune diseases matures, its role will depend not only on whether these treatments can deliver durable disease control, but also on whether the healthcare system can support their safe and practical use. Early adoption is likely to center on carefully selected patients treated through experienced centers, making coordination across neurology, hematology-oncology, and other specialties an important component of the emerging treatment model.
For developers, compelling efficacy and durability data will therefore represent only part of the equation. Long-term safety, clear patient-selection criteria, streamlined referral and treatment pathways, and robust support for physicians and patients may ultimately determine whether cell therapy remains concentrated in highly refractory populations or expands into a broader role across neuro-immune disease.